Literature DB >> 7476671

Dexrazoxane for cardiac protection against doxorubicin.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1995        PMID： 7476671

Source DB:  PubMed          Journal:  Med Lett Drugs Ther        ISSN： 0025-732X            Impact factor:   1.909


× No keyword cloud information.
  1 in total

1.  Interim Analysis of the Phase II Study: Noninferiority Study of Doxorubicin with Upfront Dexrazoxane plus Olaratumab for Advanced or Metastatic Soft-Tissue Sarcoma.

Authors:  Brian A Van Tine; Angela C Hirbe; Peter Oppelt; Ashley E Frith; Richa Rathore; Joshua D Mitchell; Fei Wan; Shellie Berry; Michele Landeau; George A Heberton; John Gorcsan; Peter R Huntjens; Yoku Soyama; Justin M Vader; Jose A Alvarez-Cardona; Kathleen W Zhang; Daniel J Lenihan; Ronald J Krone
Journal:  Clin Cancer Res       Date:  2021-03-25       Impact factor: 12.531
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.